Investing in the Future of Psychedelics
ADVISORSHARES
Email not displaying correctly?
Mental health and substance abuse is a worsening global problem:
 
 
970 million
  # of people worldwide affected by a mental illness
 
301 million
  # of people worldwide affected by an anxiety disorder
 
108 million
  # of people worldwide affected by an alcohol use disorder
 
  57 million
  # of people worldwide affected by a drug use disorder
 
Source: The Lancet, Global Burden of Disease
After decades of repression, global research into psychedelics drugs is thriving. Promising clinical studies and FDA Breakthrough Therapy designations are making psychedelic drugs a potential viable treatment for depression, post traumatic stress disorder, and various substance abuse conditions.
 
The AdvisorShares Psychedelic ETF (ticker: PSIL) invests in the nascent global psychedelic industry and those companies uncovering the emerging pharmacological benefits of psychedelic medicine.
PSIL   AdvisorShares Psychedelics ETF  
Now available. Trading
on the NYSE Arca...
 
PSIL invests in the nascent global psychedelic industry and those companies involved in the emerging pharmacological benefits of psychedelic medicine.
 
Is the only actively managed ETF offering dedicated exposure to the emerging psychedelics industry.
Invests in biotechnologypharmaceutical and life sciences companies we see leading the way in psychedelic medicine.
Based on promising research and changing legalization, psychedelics have the potential to disrupt the mental healthcare industry.
Benefits of ETF structure in the nascent psychedelics sector: diversification across and access to multiple securities in a single trade; intra-day NYSE trading liquidity5; and daily holdings transparency.
 
 
We Know Your Time Is Valuable
We Are Here for You
to an ADVISORSHARES Portfolio Manager or Investment Consultant
An AdvisorShares Investment Consultant can be reached at 1.877.843.3831 to discuss our actively managed ETF offerings. We are able to assist with special order handling to ensure that you receive the best trading execution.
Connect with Us:
Facebook Twitter LinkedIn
ADVISORSHARES |  1.877.843.3831 | www.advisorshares.com | Electronic mail policy
-For Financial Intermediary Use Only - Not For Use With The Retail Public-
 
 
Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus, a copy of which may be obtained by visiting the Fund’s website at www.AdvisorShares.com. Please read the prospectus carefully before you invest. Foreside Fund Services, LLC, distributor.
 
There is no guarantee that the Fund will achieve its investment objective. An investment in the Fund is subject to risk, including the possible loss of principal amount invested.
 
Psychedelic drugs, also known as hallucinogens, are a group of substances, including psilocybin, that are used to change and enhance sensory perceptions, thought processes, and energy levels. Psychedelic medicines, therapeutics, and healthcare treatments may be used in the treatment of illnesses such as depression, addiction, anxiety and post-traumatic stress disorder. Psychedelic medicine companies include life sciences companies having significant business activities in, or significant exposure to, the psychedelics industry including producers or distributors of psychedelic medicines, biotechnology companies engaged in research and development of psychedelic medicines, and companies that are part of the supply chain for psychedelics.
 
Psychedelics Companies Risk. Psychedelics companies are subject to various laws and regulations that may differ at the state/local and federal level. These laws and regulations may significantly affect a psychedelics company’s ability to secure financing, impact the market for psychedelics and business sales and services, and set limitations on psychedelics use, production, transportation, and storage. There can be no guarantees that such approvals or administrative actions will happen or be favorable for psychedelics companies, and such actions may be subject to lengthy delays, and may require length and expensive clinical trials. Additionally, therapies containing controlled substances may generate public controversy. Political and social pressures and adverse publicity could lead to delays in approval of, and increased expenses for, companies and any future therapeutic candidates they may develop. All of these factors and others may prevent psychedelics companies from becoming profitable, which may materially affect the value of certain Fund investments. In addition, psychedelics are subject to the risks associated with the biotechnology and pharmaceutical industries.
 
In Canada, certain psychedelic drugs, including psilocybin, are classified as Schedule III drugs under the Controlled Drugs and Substances Act (“CDSA”) and, as such, medical and recreational use is illegal under Canadian federal laws. In the United States, certain psychedelic drugs, including psilocybin, are classified as Schedule I drugs under the Controlled Substances Act (“CSA”) and the Controlled Substances Import and Export Act (the “CSIEA”) and, as such, medical and recreational use is illegal under the U.S. federal laws. There is no guarantee that psychedelic drugs or psychedelic-inspired drugs will ever be approved as medicines in either jurisdiction.
 
In the United States, scheduling determinations by the Drug Enforcement Agency (“DEA”) are dependent on Food and Drug Administration (“FDA”) approval of a substance or a specific formulation of a substance. Unless and until psilocybin, psilocin, or other psychedelics-based products receive FDA approval, such products may be prohibited from sale, which could limit the growth opportunities for certain portfolio companies of the Fund. Even if approved by the FDA, the manufacture, importation, exportation, domestic distribution, storage, sale, and legitimate use of such products will continue to be subject to a significant degree of regulation by the DEA.
 
Security prices of small cap companies may be more volatile than those of larger companies and therefore the Fund’s share price may be more volatile than those of funds that invest a larger percentage of their assets in securities issued by larger-cap companies. These risks are even greater for micro-cap companies.
 
Add alpha@advisorshares.com to your address book to ensure delivery.

ADVISORSHARES

4800 Montgomery Lane, #150, Bethesda, MD 20814

Unsubscribe - Unsubscribe Preferences